Abilene Scientist Receives Grant to Research Novel Brain Tumor Treatment
Saha to Investigate Use of Viruses to Attack, Weaken Deadly Glioblastoma Cells
An estimated 700,000 people in the U.S. are living with a brain tumor and nearly 80,000 new cases are diagnosed each year. Glioblastoma (GBM), an aggressive cancer most often found in the brain, is responsible for more than 75% of these tumors. Currently there are no effective treatments for GBM, which is almost always fatal, and most patients die 12-18 months after initial diagnosis.
In an effort to improve the prognosis for GBM patients, the U.S. Department of Defense recently awarded a $550,491 grant to Dipongkor Saha, D.V.M., Ph.D., a cancer immunologist and assistant professor of immunotherapeutics and biotechnology at the Texas Tech University Health Sciences Center (TTUHSC) Jerry H. Hodge School of Pharmacy in Abilene.
“Our goal is to develop a novel and safe treatment strategy that should provide treatment relief to a significant number of individuals suffering from this devastating disease,” Saha said.
Saha’s current research is primarily focused on inciting anti-tumor immunity, which is when the body recognizes and begins an immune response to certain antigens expressed by cancer, known as tumor associated antigens (TAAs). He is investigating the use of oncolytic virus therapy, which uses certain viruses to attack and compromise cancer cells while leaving the adjacent healthy cells to function normally. The process can kill cancer cells or weaken them so that other treatments like radiation and chemotherapy may be more effective.
In the studies proposed by his new grant, Saha said he not only will investigate how to effectively induce immunity against tumor cells, but also seek ways to divert the body’s immune system specifically toward TAAs.
“Importantly, TAAs are exclusively present in cancer cells, but absent or present at an insignificant level in healthy cells,” Saha explained. “Therefore, the TAA-targeted treatments will only kill cancer cells while sparing healthy cells, thus conferring safety to treated individuals.”
Saha’s grant funding began Sept. 1 and is scheduled to run through August 2023.
Related Stories
Molecular Pathology Preceptorship: Unmatched Value and Experience
Ericka Hendrix, PhD, MB(ASCP)CM, Program Director and Associate Professor in the Master of Science in Molecular Pathology program in the School of Health Professions spoke about the program’s preceptorship.
Moseley Named Permian Basin Regional Dean of the Texas Tech University Health Sciences Center School of Nursing
Kelly Moseley, DHSc, R.N., has been named the TTUHSC School of Nursing regional dean in the Permian Basin.
TTUHSC School of Nursing to Celebrate New YWCA Location
Community members in central Lubbock now have access to health care services and prenatal programs at one location inside the YWCA.
Recent Stories
Santos Named Department of Surgery Chair for TTUHSC School of Medicine in Lubbock
As the new Department of Surgery chair for the School of Medicine in Lubbock, Ariel Santos, M.D., M.P.H., seeks to elevate TTUHSC’s role as the Hub of Surgery for West Texas.
Covenant Health Brings Kidney Transplant Surgery Back to West Texas
The Kidney Transplant Program at Covenant Medical Center will provide life-changing opportunities for patients suffering from end-stage renal disease (ESRD) and chronic kidney conditions.
U.S. News & World Report Ranks TTUHSC Schools Among Best for 2025 Graduate School Rankings
Several graduate programs at TTUHSC have been recognized in the 2025 U.S. News & World Report Best Graduate School Rankings, reaffirming the university’s continued excellence in health sciences education and training.